Skip to main content
  • nl
  • fr
  • en
Other official information and services: www.belgium.be
Logo of the Belgian Federal Authorities
FAMHP
Your medicine and health products
  • About the FAMHP
  • Jobs
  • Publications
  • Press
  • Contact
  • Complaints
  • Webportal
  • Home
  • Human medicines
  • Veterinary medicines
    • Medicines
    • Particular products
    • Health products
  • Information for the public
  • Notification of adverse reactions or incidents
  • Home
  • Veterinary medicines
  • Medicines
    • Medicines
  • Particular products
    • Raw materials
    • Specially reglemented substances
    • Grey area
  • Health products
    • Medical devices and their accessories

Medicines for veterinary use

  • Scientific-Technical Advice
    • Introduction
    • Procedures
    • Regulation
    • Fees
    • FAQ's
    • Workshops and Training
    • National Innovation Office: consultation procedure
  • Research & Development
    • Clinical trials
  • Marketing Authorisation procedures
    • Types
    • Requirements
    • eSubmission
    • Parallel import
    • MRL
    • Practical informations
  • Pharmacovigilance
    • BCVP
    • Veterinary pharmacovigilance in Europe
    • Responsible for pharmacovigilance
    • Inspections
  • Production
    • Good Manufacturing Practice
    • Qualified person
  • Distribution & delivery
    • Good Distribution Practice
    • Marketing/ Unavailability
    • Sunset clause
    • Full-line wholesalers
    • Pharmacies for the public
    • Veterinary depots
    • Cascade system
    • Fiscal importation of medicinal products from third countries: clarification of the provisions
  • Authorisation - Certificates
    • Authorisation RD 14/12/2006
    • Certificates application
    • Templates certificates
    • Certificates prices
  • Declarations
    • Medicines for export
    • Manufacturing activity as a sub-contractor
  • Proper use
    • Information for a proper use
    • Withdrawal periods
    • Advertising
    • Responsible for information
Last updated on 30/12/2008

Notification of adverse reactions or incidents

PIL and SPC
of a medicine

(PIL: patient information leaflet SPC: summary of product characteristics)

Search

News

25/05/2018
PRAC May 2018 – Recommendation to suspend hydroxyethyl-starch (HES) solutions for infusion, new measures for Esmya, end of the review of Zinbryta and precautionary advice on HIV medicine
22/05/2018
Give your opinion on a clinical trial with genetically modified polio vaccines
15/05/2018
Update on the new Clinical Trial Regulation pilot project
15/05/2018
New guidance for submission of clinical trial applications, substantial amendment notifications and end of trial declarations to the R&D (human) Division of the FAMHP.
All news

© 2016 - FAMHP

  • Site map
  • Disclaimer
  • Complaints
  • Contact